Roche、Genmab和Genentech的实验药物在治疗眼癌、子宫癌和乳腺癌方面显示出希望,但还没有获得批准。 Experimental drugs from Roche, Genmab, and Genentech show promise in treating eye, uterine, and breast cancers, but none are approved yet.

Roche的实验性药物Vamikibart以IL-6为目标,显示在第三阶段对冲积结膜水肿的试验中,视力显著改善,视网膜肿胀减少,这是导致视力丧失的一个主要原因。 Roche’s experimental drug vamikibart, targeting IL-6, showed significant improvement in vision and reduced retinal swelling in Phase III trials for uveitic macular edema, a leading cause of vision loss. Genmab的Rina-S在晚期子宫颈癌的早期试验中实现了50%的回复率,为选择不多的病人带来了希望。 Genmab’s Rina-S achieved a 50% response rate in early trials for advanced endometrial cancer, offering hope for patients with few options. 基因科技(Genenenetch)的合成疗法改善了高级HR+/HER2-乳腺癌的无进展生存,提出了一条有希望的新治疗途径。 Genentech’s giredestrant combination therapy improved progression-free survival in advanced HR+/HER2- breast cancer, suggesting a promising new treatment path. 尚未批准任何药品,有待进一步分析。 None of the drugs have yet been approved, and further analysis is pending.